Life Scientist > Biotechnology

In brief: Imugene; Cryptome

17 January, 2005 by Staff Writers

Imugene (ASX: IMU) has been granted patent protection for its Receptor Mimic Technology (RMT) in the United States.


APAF, Qiagen team on $1m proteomics project

17 January, 2005 by Graeme O'Neill

The Australian Proteome Analysis Facility, headquartered at Sydney's Macquarie University, is to team up with global life science supplier Qiagen in a AUD$1m research project to develop more efficient ways of removing high-abundance proteins from serum samples.


Metabolic's Belyea happy to focus on science

14 January, 2005 by Melissa Trudinger

Metabolic Pharmaceuticals' CEO Chris Belyea is looking forward to stepping down from the hot seat and focusing on the science and technology aspects of biotechnology.


Visiomed blows hot

13 January, 2005 by Graeme O'Neill

Shares in Visionmed (ASX:VSG) rose 1.3 cents to 4.4 cents today, before relaxing to 4.3 cents, on news that the Perth medical-device company is gearing up to market and distribute its Funhaler asthma spacer device for children in the US.


Virax raises $3.25 million

13 January, 2005 by Renate Krelle

Virax (ASX:VHL) has secured $3.25 million of the $4 million it was aiming to raise through a non-renounceable share purchase plan.


Narhex float loses ground

12 January, 2005 by Renate Krelle

Shares in Sydney anti-viral drug developer Narhex Life Sciences' (ASX:NLS) made a promising debut this morning, listing at 4 cents above their $0.20 issue price. However they failed to maintain momentum, and at time of writing had dropped to $0.19.


Narhex drug proves multi-talented

11 January, 2005 by Graeme O'Neill

Sydney anti-viral drug developer Narhex Life Sciences has one of the world's most promising drugs for HIV/AIDS. Could it also have, in the same drug, a potential treatment for Hepatitis B?


In brief: Biodiem; Avexa

11 January, 2005 by Staff Writers

BioDiem (ASX:BDM) has received a US$1m signing-on payment, the first in a number of milestone payments due under its US$8m licence agreement with Akzo Nobel's Nobilon.


Biotech stocks tread water in 2004

11 January, 2005 by Renate Krelle

Despite a boom in IPO activity, retail and institutional investors left biotechnology stocks on the shelf in 2004, two sector indices have revealed. The Southern Cross Equities Australian Biotechnology Index declined 5 per cent in 2004, and the 80-company Intersuisse Biotechnology index - bolstered by some larger stocks including Cochlear (ASX:COH) and Resmed (ASX:RMD) -- edged forward only 0.16 per cent over the year.


Rockeby awaits US marketing approval

11 January, 2005 by Renate Krelle

Singapore's Rockeby biomed (ASX:RBY) is a step closer to gaining US marketing approval for its candiadiasis diagnostics, Syscan3 and Candia5, having released results of its US 510(k) study which confirmed that both tests are effective as diagnostic aids when used in conjunction with microscopy and microbiological culture.


Peplin cheered by sunspot trial results

10 January, 2005 by Graeme O'Neill

Shares in Peplin Biotech (ASX:PEP) jumped today when the company announced that full analysis of the data from its Phase I safety and tolerability trial had provided "hugely exciting" results: in 40 per cent of cases, a single application of its PEP005 topical gel for pre-cancerous skin 'sunspots' completely or substantially cleared the volunteers' actinic keratoses (AK), compared with 15 per cent for placebo patients.


Metabolic hits back at drug trial criticism

17 December, 2004 by Renate Krelle and Melissa Trudinger

Metabolic (ASX:MBP) today did its best to salvage its reputation and share price, hitting back at analyst criticism of its Phase II clinical trial results of its obesity drug AOD9604.


In brief: Proteome Systems, EpiTan, Genesis R&D

17 December, 2004 by Renate Krelle

Confirming its ambitions to move into drug development, Sydney-based Proteome Systems (ASX:PXL) has signed a contract to acquire US antioxidant drug-developer Eukarion. The acquisition involves a cash payment of up to AUD$150,000 in up-front consideration, and an an initial equity issue by Proteome Systems of approximately 1.7 million shares.


Heartware to lodge prospectus despite litigation rumours

17 December, 2004 by Renate Krelle

US artificial heart firm Heartware will today lodge its prospectus with ASIC, for an ASX-listing schedule to take place in late January, despite rumours of a possible patent battle with Australian artificial heart firm Ventracor (ASX:VCR).


In brief: Chemeq; C3; Gropep; Starpharma; Meditech

16 December, 2004 by Staff Writers

Non-executive director Paul Grujic and chief financial officer Ian Purdy today resigned from West Australian biotech Chemeq (ASX: CMQ).


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd